TNSN00111A1 - Hydroxamides d'acides 3-(arylsulfonylamino)-tetrahydropyranne-3- carboxyliques, procede pour leur preparation et compositions pharmaceutiques les contenant - Google Patents
Hydroxamides d'acides 3-(arylsulfonylamino)-tetrahydropyranne-3- carboxyliques, procede pour leur preparation et compositions pharmaceutiques les contenantInfo
- Publication number
- TNSN00111A1 TNSN00111A1 TNTNSN00111A TNSN00111A TNSN00111A1 TN SN00111 A1 TNSN00111 A1 TN SN00111A1 TN TNSN00111 A TNTNSN00111 A TN TNSN00111A TN SN00111 A TNSN00111 A TN SN00111A TN SN00111 A1 TNSN00111 A1 TN SN00111A1
- Authority
- TN
- Tunisia
- Prior art keywords
- tetrahydropyranne
- carboxyliques
- arylsulfonylamino
- preparation
- pharmaceutical compositions
- Prior art date
Links
- 239000002253 acid Substances 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 201000011510 cancer Diseases 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 abstract 2
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 abstract 1
- WEAHRLBPCANXCN-UHFFFAOYSA-N Daunomycin Natural products CCC1(O)CC(OC2CC(N)C(O)C(C)O2)c3cc4C(=O)c5c(OC)cccc5C(=O)c4c(O)c3C1 WEAHRLBPCANXCN-UHFFFAOYSA-N 0.000 abstract 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 abstract 1
- 229930012538 Paclitaxel Natural products 0.000 abstract 1
- 229940009456 adriamycin Drugs 0.000 abstract 1
- 229930013930 alkaloid Natural products 0.000 abstract 1
- 229940035676 analgesics Drugs 0.000 abstract 1
- 239000000730 antalgic agent Substances 0.000 abstract 1
- 206010003246 arthritis Diseases 0.000 abstract 1
- 238000002648 combination therapy Methods 0.000 abstract 1
- 229940111134 coxibs Drugs 0.000 abstract 1
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 abstract 1
- 231100000433 cytotoxic Toxicity 0.000 abstract 1
- 230000001472 cytotoxic effect Effects 0.000 abstract 1
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 abstract 1
- 229960005420 etoposide Drugs 0.000 abstract 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 abstract 1
- 201000008482 osteoarthritis Diseases 0.000 abstract 1
- 229960001592 paclitaxel Drugs 0.000 abstract 1
- 229910052697 platinum Inorganic materials 0.000 abstract 1
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Substances [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 abstract 1
- 206010039073 rheumatoid arthritis Diseases 0.000 abstract 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 abstract 1
- 229940063683 taxotere Drugs 0.000 abstract 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 abstract 1
- 229960004528 vincristine Drugs 0.000 abstract 1
- -1 vincristine Natural products 0.000 abstract 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/16—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D309/28—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D309/14—Nitrogen atoms not forming part of a nitro radical
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Oncology (AREA)
- Heart & Thoracic Surgery (AREA)
- Communicable Diseases (AREA)
- Cardiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Dermatology (AREA)
- Virology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Endocrinology (AREA)
- Ophthalmology & Optometry (AREA)
- Hospice & Palliative Care (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
Abstract
L’INVENTION CONCERNE DES COMPOSES DE FORMULE I : DANS LAQUELLE R1, R2, R3, R4, ET Q REPRESENTENT DIVERS RADICAUX. ELLE CONCERNE EGALEMENT UN PROCEDE POUR LEUR PREPARATION ET DES COMPOSITIONS PHARMACEUTIQUES LES CONTENANT. APPLICATION : UTILISATION DE CES COMPOSES ET COMPOSITIONS, COMME INHIBITEURS D’ENZYMES, POUR LE TRAITEMENT DE DIVERSES MALADIES.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13653099P | 1999-05-28 | 1999-05-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TNSN00111A1 true TNSN00111A1 (fr) | 2002-05-30 |
Family
ID=22473239
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TNTNSN00111A TNSN00111A1 (fr) | 1999-05-28 | 2000-05-24 | Hydroxamides d'acides 3-(arylsulfonylamino)-tetrahydropyranne-3- carboxyliques, procede pour leur preparation et compositions pharmaceutiques les contenant |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US6197810B1 (fr) |
| EP (1) | EP1181286B1 (fr) |
| JP (1) | JP3784645B2 (fr) |
| AT (1) | ATE254119T1 (fr) |
| AU (1) | AU4424000A (fr) |
| BR (1) | BR0011539A (fr) |
| CA (1) | CA2375524C (fr) |
| DE (1) | DE60006523T2 (fr) |
| DK (1) | DK1181286T3 (fr) |
| DZ (1) | DZ3046A1 (fr) |
| ES (1) | ES2208315T3 (fr) |
| GT (1) | GT200000079A (fr) |
| HN (1) | HN2000000074A (fr) |
| MA (1) | MA26738A1 (fr) |
| MX (1) | MXPA01012265A (fr) |
| PA (1) | PA8495901A1 (fr) |
| PE (1) | PE20010170A1 (fr) |
| PT (1) | PT1181286E (fr) |
| SV (1) | SV2001000086A (fr) |
| TN (1) | TNSN00111A1 (fr) |
| UY (1) | UY26167A1 (fr) |
| WO (1) | WO2000073295A1 (fr) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040122011A1 (en) * | 1998-12-23 | 2004-06-24 | Pharmacia Corporation | Method of using a COX-2 inhibitor and a TACE inhibitors as a combination therapy |
| NZ520657A (en) | 2000-03-21 | 2004-11-26 | Procter & Gamble | Heterocyclic side chain containing, N-substituted metalloprotease inhibitors |
| HUP0300262A2 (hu) * | 2000-03-21 | 2003-06-28 | The Procter And Gamble Co. | Heterociklusos oldalláncot tartalmazó metalloproteáz inhibitorok |
| EP1265865A2 (fr) | 2000-03-21 | 2002-12-18 | The Procter & Gamble Company | Inhibiteurs de metalloproteases d'acide difluorobutyrique |
| US7019376B2 (en) * | 2000-08-11 | 2006-03-28 | Reflectivity, Inc | Micromirror array device with a small pitch size |
| US20030045449A1 (en) * | 2001-08-15 | 2003-03-06 | Pfizer, Inc. | Pharmaceutical combinations for the treatment of neurodegenerative diseases |
| GB0319069D0 (en) * | 2003-08-14 | 2003-09-17 | Glaxo Group Ltd | Therapeutically useful compounds |
| US20050058611A1 (en) * | 2003-08-22 | 2005-03-17 | L'oreal | Preventing and/or combating collagen fiber degradation induced under conditions of natural exposure to sunlight |
| CN102348697B (zh) | 2009-01-12 | 2014-12-10 | 辉瑞股份有限公司 | 磺酰胺衍生物 |
| WO2012004706A2 (fr) | 2010-07-09 | 2012-01-12 | Pfizer Limited | Composés chimiques |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5455258A (en) * | 1993-01-06 | 1995-10-03 | Ciba-Geigy Corporation | Arylsulfonamido-substituted hydroxamic acids |
| NZ336840A (en) | 1997-02-03 | 2001-01-26 | Pfizer Prod Inc | Arylsulfonylamino hydroxamic acid derivatives useful in the treatment of tumor necrosis factor and matrix metalloproteinase mediated diseases |
| PA8469501A1 (es) * | 1998-04-10 | 2000-09-29 | Pfizer Prod Inc | Hidroxamidas del acido (4-arilsulfonilamino)-tetrahidropiran-4-carboxilico |
-
2000
- 2000-05-15 AT AT00925520T patent/ATE254119T1/de not_active IP Right Cessation
- 2000-05-15 WO PCT/IB2000/000647 patent/WO2000073295A1/fr not_active Ceased
- 2000-05-15 ES ES00925520T patent/ES2208315T3/es not_active Expired - Lifetime
- 2000-05-15 AU AU44240/00A patent/AU4424000A/en not_active Abandoned
- 2000-05-15 DK DK00925520T patent/DK1181286T3/da active
- 2000-05-15 HN HN2000000074A patent/HN2000000074A/es unknown
- 2000-05-15 DE DE60006523T patent/DE60006523T2/de not_active Expired - Fee Related
- 2000-05-15 JP JP2000621361A patent/JP3784645B2/ja not_active Expired - Fee Related
- 2000-05-15 CA CA002375524A patent/CA2375524C/fr not_active Expired - Fee Related
- 2000-05-15 BR BR0011539-8A patent/BR0011539A/pt not_active IP Right Cessation
- 2000-05-15 EP EP00925520A patent/EP1181286B1/fr not_active Expired - Lifetime
- 2000-05-15 MX MXPA01012265A patent/MXPA01012265A/es active IP Right Grant
- 2000-05-15 PT PT00925520T patent/PT1181286E/pt unknown
- 2000-05-19 PA PA20008495901A patent/PA8495901A1/es unknown
- 2000-05-24 TN TNTNSN00111A patent/TNSN00111A1/fr unknown
- 2000-05-24 MA MA25988A patent/MA26738A1/fr unknown
- 2000-05-24 DZ DZ000090A patent/DZ3046A1/fr active
- 2000-05-25 GT GT200000079A patent/GT200000079A/es unknown
- 2000-05-26 UY UY26167A patent/UY26167A1/es not_active Application Discontinuation
- 2000-05-26 US US09/579,059 patent/US6197810B1/en not_active Expired - Fee Related
- 2000-05-26 SV SV2000000086A patent/SV2001000086A/es not_active Application Discontinuation
- 2000-05-26 PE PE2000000507A patent/PE20010170A1/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| MXPA01012265A (es) | 2002-07-30 |
| PE20010170A1 (es) | 2001-02-27 |
| CA2375524C (fr) | 2006-11-28 |
| MA26738A1 (fr) | 2004-12-20 |
| UY26167A1 (es) | 2000-12-29 |
| EP1181286A1 (fr) | 2002-02-27 |
| HN2000000074A (es) | 2001-02-02 |
| PT1181286E (pt) | 2004-02-27 |
| DZ3046A1 (fr) | 2004-03-27 |
| ATE254119T1 (de) | 2003-11-15 |
| DE60006523D1 (de) | 2003-12-18 |
| JP2003500485A (ja) | 2003-01-07 |
| DK1181286T3 (da) | 2004-02-16 |
| BR0011539A (pt) | 2002-02-26 |
| EP1181286B1 (fr) | 2003-11-12 |
| US6197810B1 (en) | 2001-03-06 |
| DE60006523T2 (de) | 2004-08-12 |
| ES2208315T3 (es) | 2004-06-16 |
| CA2375524A1 (fr) | 2000-12-07 |
| SV2001000086A (es) | 2001-11-08 |
| PA8495901A1 (es) | 2002-08-26 |
| JP3784645B2 (ja) | 2006-06-14 |
| GT200000079A (es) | 2001-11-16 |
| AU4424000A (en) | 2000-12-18 |
| WO2000073295A1 (fr) | 2000-12-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TNSN99157A1 (fr) | Derives d'hydroxamides heterocycliques nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant | |
| YU5201A (sh) | Derivati hidroksipipekolathidroksamske kiseline kao inhibitori mmp | |
| EA199900641A1 (ru) | Производные арилсульфонилгидроксамовой кислоты | |
| AP9801174A0 (en) | Cyclic sulfone derivatives. | |
| CA2279276A1 (fr) | Derives d'acide arylsulfonylaminohydroxamique | |
| GEP20053673B (en) | Aryl or Heteroaryl Fused Imidazole Compounds as Anti-Inflammatory and Analgesic Agents | |
| IS2114B (is) | Kínasólínafleiður til að meðhöndla æxli | |
| EA199900036A1 (ru) | Ингибиторы металлопротеаз матрикса на основе фосфинатов, фармацевтическая композиция, способ лечения | |
| DZ3020A1 (fr) | Acides oxamiques nouveaux, procédé pour leur préparation et compositions pharmaceutiques les contenant. | |
| NO990821L (no) | Arylsulfonylamino-hydroksaminsyre-derivater | |
| BG106694A (en) | Heterocyclo-alkylsulfonyl pyrazole derivatives as anti-inflammatory/analgesic agents | |
| MA26738A1 (fr) | Hydroxamides d'acides 3-(arylsulfonylamino)-tetrahydropyranne-3-carboxyliques, procede pour leur preparation et compositions pharmaceutiques les contenant | |
| TNSN00114A1 (fr) | Hydroxamides d'acide 3-(arylsulfonylamino)-tetrahydrofuranne-3- carboxyliques, procede pour leur preparation et compositions pharmaceutiques les contenant | |
| DZ3048A1 (fr) | Précurseurs médicamenteux mutuels d'amlopidine et d'atorvastine, procédé pour leur préparation et compositions pharmaceutiques les contenant. | |
| CA2392271A1 (fr) | Sulfonylheteroaryltriazoles comme agents anti-inflammatoires/analgesiques | |
| DZ3040A1 (fr) | Benzolactames et thioamides cycliques substitués nouveaux, procédé pour préparation et compositions pharmaceutiques les contenant. | |
| EP2054398A4 (fr) | Nouveaux composés hétérocycliques contenant des atomes d'azote ou des sels acceptables de ceux-ci du point de vue pharmaceutique, procédé permettant de les préparer et composition pharmaceutique comprenant ceux-ci pour le traitement du cancer | |
| FR2880889B1 (fr) | Derives de l'acide 1h-indole-3-carboxylique, procedes pour leur preparation, compositions pharmaceutiques les contenant et applications en therapeutique |